Allogene Therapeutics (ALLO) Non-Current Assets (2019 - 2025)
Historic Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $179.1 million.
- Allogene Therapeutics' Non-Current Assets fell 3710.96% to $179.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $828.7 million, marking a year-over-year decrease of 240.85%. This contributed to the annual value of $245.3 million for FY2024, which is 3353.0% up from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Non-Current Assets is $179.1 million, which was down 3710.96% from $187.9 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Non-Current Assets registered a high of $579.5 million during Q4 2021, and its lowest value of $179.1 million during Q3 2025.
- Its 5-year average for Non-Current Assets is $324.7 million, with a median of $270.9 million in 2023.
- Its Non-Current Assets has fluctuated over the past 5 years, first surged by 15147.22% in 2021, then plummeted by 4948.19% in 2022.
- Over the past 5 years, Allogene Therapeutics' Non-Current Assets (Quarter) stood at $579.5 million in 2021, then crashed by 49.48% to $292.8 million in 2022, then crashed by 37.24% to $183.7 million in 2023, then skyrocketed by 33.53% to $245.3 million in 2024, then decreased by 27.01% to $179.1 million in 2025.
- Its Non-Current Assets stands at $179.1 million for Q3 2025, versus $187.9 million for Q2 2025 and $216.4 million for Q1 2025.